Clinical Research Directory
Browse clinical research sites, groups, and studies.
Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Summary
The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate polypeptide sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the polypeptide vaccine for immunotherapy of human cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the polypeptide vaccine immunotherapy on human cancers will firstly be evaluated.
Official title: Anti-cancer Neoantigen Polypeptide Vaccine to Treat Advanced Solid Tumors: Phase I Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-06-04
Completion Date
2037-12-30
Last Updated
2024-06-26
Healthy Volunteers
No
Conditions
Interventions
Neoantigen Polypeptide Vaccine
Deliver neoantigen polypeptide vaccine into patients for anti-ancer therapy.
Locations (1)
Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, China